Gesynta Pharma Patents

Patent portfolio assigned to Gesynta Pharma (verified via public assignee records). Stockholm clinical-stage pharma (Karolinska Institutet spin-out) developing mPGES-1 inhibitors (vipoglanstat/GS-248). Patents confirmed: listed as original assignee of US8759537B2 (3H-imidazo[4,5-C]pyridine-6-carboxamides) and assigned AU2011290725 from Boehringer Ingelheim. Exact patent count not visible on a fetched page. Clinical-stage, so no named customers; no direct competitors sourced.